⚕ GalenOps field
←

SITE015-0005

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-02-15

AEs
6
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-31 (study day 89); relationship: N

mild assessed

Grade 1 Adrenal insufficiency — outcome: RECOVERED/RESOLVED; onset 2022-06-24 (study day 113); relationship: not assessed

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-15 (study day 165); relationship: Y

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-26 (study day 176); relationship: N

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-31 (study day 181); relationship: not assessed

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-02 (study day 244); relationship: not assessed

Data queries

No data queries.